Literature DB >> 7877620

Transmembrane domain interactions are necessary for negative cooperativity of the insulin receptor.

J Whittaker1, P Garcia, G Q Yu, D C Mynarcik.   

Abstract

Insulin binding to the human insulin receptor (HIR) is characterized by negatively cooperative site-site interactions that give rise to a curvilinear Scatchard plot. Insulin binding to recombinant secreted HIRs is linear, suggesting that interactions between the transmembrane or cytoplasmic domains of the receptor heterodimers may be responsible for the generation of negative cooperativity. To determine the domains responsible, a series of HIR cDNAs encoding C-terminal deletion mutations was constructed; HIR.delta CT, HIR.delta TK, HIR.delta TMCP-encoded deletions of the tyrosine kinase regulatory, the tyrosine kinase regulatory and catalytic, the cytoplasmic and the transmembrane and cytoplasmic domains, respectively. When expressed in COS cells, all cDNAs were processed to mature alpha- and beta- subunits. The affinity of HIR.delta CT, HIR.delta TK, and HIR.delta CP for insulin were 2- to 3-fold greater than that of wild type HIR (HIR.WT) which was 4- to 5-fold greater than that of HIR.delta TMCP. Scatchard plots of HIR.delta CT, HIR.delta TK, and HIR.delta CP, like that of HIR.WT, were curvilinear. In contrast, that of HIR.delta TMCP was linear. We conclude that constraints imposed on HIR structure by membrane insertion and/or interactions between receptor transmembrane domains are essential for the generation of negative cooperativity. Further, interactions between the C-terminal regions of the cytoplasmic domains appear to modulate affinity for insulin.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7877620     DOI: 10.1210/mend.8.11.7877620

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  8 in total

1.  Mutational analysis of the N-linked glycosylation sites of the human insulin receptor.

Authors:  T C Elleman; M J Frenkel; P A Hoyne; N M McKern; L Cosgrove; D R Hewish; K M Jachno; J D Bentley; S E Sankovich; C W Ward
Journal:  Biochem J       Date:  2000-05-01       Impact factor: 3.857

2.  Biology using engineering tools: the negative feedback amplifier.

Authors:  Marc R Birtwistle; Walter Kolch
Journal:  Cell Cycle       Date:  2011-07-01       Impact factor: 4.534

3.  Hormone-triggered conformational changes within the insulin-receptor ectodomain: requirement for transmembrane anchors.

Authors:  R R Flörke; K Schnaith; W Passlack; M Wichert; L Kuehn; M Fabry; M Federwisch; H Reinauer
Journal:  Biochem J       Date:  2001-11-15       Impact factor: 3.857

4.  High-affinity insulin binding: insulin interacts with two receptor ligand binding sites.

Authors:  Linda Whittaker; Caili Hao; Wen Fu; Jonathan Whittaker
Journal:  Biochemistry       Date:  2008-12-02       Impact factor: 3.162

5.  Symmetric and asymmetric receptor conformation continuum induced by a new insulin.

Authors:  Xiaochun Xiong; Alan Blakely; Jin Hwan Kim; John G Menting; Ingmar B Schäfer; Heidi L Schubert; Rahul Agrawal; Theresia Gutmann; Carlie Delaine; Yi Wolf Zhang; Gizem Olay Artik; Allanah Merriman; Debbie Eckert; Michael C Lawrence; Ünal Coskun; Simon J Fisher; Briony E Forbes; Helena Safavi-Hemami; Christopher P Hill; Danny Hung-Chieh Chou
Journal:  Nat Chem Biol       Date:  2022-03-14       Impact factor: 16.174

Review 6.  Theoretical and computational studies of peptides and receptors of the insulin family.

Authors:  Harish Vashisth
Journal:  Membranes (Basel)       Date:  2015-02-11

7.  Cryo-EM structure of the complete and ligand-saturated insulin receptor ectodomain.

Authors:  Theresia Gutmann; Ingmar B Schäfer; Chetan Poojari; Beate Brankatschk; Ilpo Vattulainen; Mike Strauss; Ünal Coskun
Journal:  J Cell Biol       Date:  2020-01-06       Impact factor: 10.539

8.  All-Atom Structural Models of the Transmembrane Domains of Insulin and Type 1 Insulin-Like Growth Factor Receptors.

Authors:  Hossein Mohammadiarani; Harish Vashisth
Journal:  Front Endocrinol (Lausanne)       Date:  2016-06-20       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.